Ovid Therapeutics Unveils Pipeline Advances Targeting Drug-Resistant Epilepsy and Neuropsychiatric Disorders

Reuters01-13

Ovid <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Unveils Pipeline Advances Targeting Drug-Resistant Epilepsy and Neuropsychiatric Disorders

Ovid Therapeutics Inc. has provided an update on its neurotherapeutics pipeline targeting conditions associated with neural hyperexcitability, including drug-resistant epilepsies and neuropsychiatric disorders. The company highlighted its lead program, OV329, a GABA-aminotransferase inhibitor being developed for drug-resistant adult focal onset seizures. Phase 1 findings for OV329 are expected in early 2026, with a Phase 2a trial initiation planned for the second quarter of 2026 and topline results anticipated in mid-2027. Ovid is also advancing oral candidates OV4071 and OV4041 for indications such as psychosis associated with Parkinson's disease, Lewy body dementia, schizophrenia, generalized anxiety disorder, and Rett syndrome. The company reported it has sufficient cash runway expected to fund operations into the second half of 2028. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief on January 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603522074?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 08:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603522074","market":"nz","top_or_hot":-1,"title":"Ovid Therapeutics Unveils Pipeline Advances Targeting Drug-Resistant Epilepsy and Neuropsychiatric Disorders","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ovid <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Pipeline Advances Targeting Drug-Resistant Epilepsy and Neuropsychiatric Disorders\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/OVID\">Ovid Therapeutics Inc.</a> has provided an update on its neurotherapeutics pipeline targeting conditions associated with neural hyperexcitability, including drug-resistant epilepsies and neuropsychiatric disorders. The company highlighted its lead program, OV329, a GABA-aminotransferase inhibitor being developed for drug-resistant adult focal onset seizures. Phase 1 findings for OV329 are expected in early 2026, with a Phase 2a trial initiation planned for the second quarter of 2026 and topline results anticipated in mid-2027. Ovid is also advancing oral candidates OV4071 and OV4041 for indications such as psychosis associated with Parkinson's disease, Lewy body dementia, schizophrenia, generalized anxiety disorder, and Rett syndrome. The company reported it has sufficient cash runway expected to fund operations into the second half of 2028. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief on January 13, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ovid Therapeutics Unveils Pipeline Advances Targeting Drug-Resistant Epilepsy and Neuropsychiatric Disorders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOvid Therapeutics Unveils Pipeline Advances Targeting Drug-Resistant Epilepsy and Neuropsychiatric Disorders\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-13 08:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ovid <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Pipeline Advances Targeting Drug-Resistant Epilepsy and Neuropsychiatric Disorders\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/OVID\">Ovid Therapeutics Inc.</a> has provided an update on its neurotherapeutics pipeline targeting conditions associated with neural hyperexcitability, including drug-resistant epilepsies and neuropsychiatric disorders. The company highlighted its lead program, OV329, a GABA-aminotransferase inhibitor being developed for drug-resistant adult focal onset seizures. Phase 1 findings for OV329 are expected in early 2026, with a Phase 2a trial initiation planned for the second quarter of 2026 and topline results anticipated in mid-2027. Ovid is also advancing oral candidates OV4071 and OV4041 for indications such as psychosis associated with Parkinson's disease, Lewy body dementia, schizophrenia, generalized anxiety disorder, and Rett syndrome. The company reported it has sufficient cash runway expected to fund operations into the second half of 2028. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief on January 13, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL3qT2s:1","article_id":"2603522074","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603522074","pubTimestamp":1768263257,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ovid Therapeutics Inc. has provided an update on its neurotherapeutics pipeline targeting conditions associated with neural hyperexcitability, including drug-resistant epilepsies and neuropsychiatric disorders. The company highlighted its lead program, OV329, a GABA-aminotransferase inhibitor being developed for drug-resistant adult focal onset seizures. Phase 1 findings for OV329 are expected in early 2026, with a Phase 2a trial initiation planned for the second quarter of 2026 and topline results anticipated in mid-2027. Ovid is also advancing oral candidates OV4071 and OV4041 for indications such as psychosis associated with Parkinson's disease, Lewy body dementia, schizophrenia, generalized anxiety disorder, and Rett syndrome. The company reported it has sufficient cash runway expected to fund operations into the second half of 2028. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificia","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","OVID":"Ovid Therapeutics Inc."},"translate_title":"Ovid Therapeutics公布针对耐药性癫痫和神经精神疾病的管道进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OVID":0.9},"content_text":"Ovid Therapeutics Unveils Pipeline Advances Targeting Drug-Resistant Epilepsy and Neuropsychiatric Disorders\n    \n\nOvid Therapeutics Inc. has provided an update on its neurotherapeutics pipeline targeting conditions associated with neural hyperexcitability, including drug-resistant epilepsies and neuropsychiatric disorders. The company highlighted its lead program, OV329, a GABA-aminotransferase inhibitor being developed for drug-resistant adult focal onset seizures. Phase 1 findings for OV329 are expected in early 2026, with a Phase 2a trial initiation planned for the second quarter of 2026 and topline results anticipated in mid-2027. Ovid is also advancing oral candidates OV4071 and OV4041 for indications such as psychosis associated with Parkinson's disease, Lewy body dementia, schizophrenia, generalized anxiety disorder, and Rett syndrome. The company reported it has sufficient cash runway expected to fund operations into the second half of 2028. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief on January 13, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603522074","isCrawlerRequest":true}